Antibiotic produced by Streptomyces strains: D. Hendlin et al., Science 166, 122 (1969); B. G. Christensen et al., ibid. 123; also produced by Pseudomonas syringae: J. Shogi et al., J. Antibiot. 39, 1011 (1986). Isoln: D. Hendlin et al., BE 718507; eidem, US 3914231 (1969, 1975 both to Merck & Co.). Synthesis and resolution: B. G. Christensen et al., BE 723072; BE 723073 (both 1969 to Merck & Co.). Alternate synthesis: Girotra, Wendler, Tetrahedron Lett. 1969, 4647; Glamkowski et al., J. Org. Chem. 35, 3510 (1970). Series of articles on characterization, activity and clinical testing: Antimicrob. Agents Chemother. 1969, 284-351; H. B. Woodruff et al., Chemotherapy 23, Suppl. 1, 1-22 (1977). Mechanism of action: Kahan et al., Ann. N.Y. Acad. Sci. 235, 354 (1974). Pharmacokinetics in humans: M. Goto et al., Antimicrob. Agents Chemother. 20, 393 (1981). Pharmacology of cofosfolactamines, fixed dose combinations of fosfomycin with β-lactam antibiotics: P. Periti, Drugs Exp. Clin. Res. 6, 305 (1980); and clinical trial: T. Barreca et al., ibid. 10, 55 (1984). Electrophoretic determn in biological fluids: D. Levêque et al., J. Chromatogr. B 655, 320 (1994). Clinical trial in cystic fibrosis: A. Mirakhur et al., J. Cyst. Fibros. 2, 19 (2003).
Clinical trial in urinary tract infection: G. Bonfiglio et al., Chemotherapy (Basel) 51, 162 (2005).
Antibacterial.
Antibacterial (Antibiotics)